Microgels for localized immune control in beta cell replacement
NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases
About This Grant
PROJECT SUMMARY / ABSTRACT The objective of this project is to induce localized immune tolerance to transplanted human beta cells derived from renewable stem cell sources as a treatment for type 1 diabetes. We will test our approach to prevent immune rejection of grafted human stem cell derived beta cells in diabetic mice with elements of human immune systems. In addition, we seek to explain the detailed biological mechanisms by which the therapy works by conducting in vitro studies using islet-reactive human T cells. Recent advances in the generation of stem cell derived beta-like cells (sBCs) have raised the possibility of providing a renewable source of functional beta cells for transplantation, effectively overcoming the severe shortage of human donor islets. We have generated simplified culture and cryo-storage conditions that accurately and efficiently generate unlimited quantities of glucose-responsive insulin-expressing beta cells in vitro. Stem cell derived beta cells generated have already been used successfully for beta cell replacement therapy in animal models and in human clinical trials. By combining cell engineering with biomaterials engineering to display negative regulators of immunity (e.g. anti- CD3 and CD155), we will functionalize stem cell derived beta cells (sBCs) to counter autoimmunity upon transplantation. A major strength of our approach is the use of non-animal in vitro models of human type 1 diabetes alongside humanized preclinical models. We hypothesize that CD155 expressing stem cell derived human pseudo islets combined with anti-CD3 microgels will be resistant to autoimmune destruction and exhibit enhanced engraftment / survival. Our strategy will induce localized tolerance to beta cell antigens while simultaneously promoting sBC graft vascularization.
Grant Summary
Microgels for localized immune control in beta cell replacement is a NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases grant providing up to $736K for university, nonprofit, healthcare org. Applications are due 2031-05-31 (open). Check eligibility and apply with FindGrants.
Not quite the right fit?
Search 9,000+ open grants, or get matches ranked for your organization — free.
Focus Areas
Eligibility
How to Apply
Up to $736K
2031-05-31
- 1Confirm your organization is eligible for Microgels for localized immune control in beta cell replacement from NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases, checking organization type, location, and any population or project requirements.
- 2Gather the required documents and information, including your organization details, project plan, and budget figures.
- 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
- 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases before the deadline.
Don't want to draft it yourself?
We'll draft the complete application against NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.
AI Requirement Analysis
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
Microgels for localized immune control in beta cell replacement: Frequently Asked Questions
Who is eligible for the Microgels for localized immune control in beta cell replacement?
Microgels for localized immune control in beta cell replacement is offered by NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases and is generally open to university, nonprofit, healthcare org. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.
How much funding does the Microgels for localized immune control in beta cell replacement provide?
Microgels for localized immune control in beta cell replacement provides up to $736K per award from NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.
When is the Microgels for localized immune control in beta cell replacement deadline?
Applications for Microgels for localized immune control in beta cell replacement are due 2031-05-31 (open). Because deadlines can change, verify the date with the funder, NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases, and give yourself enough time to prepare a complete, competitive application before the close date.
How do you apply for the Microgels for localized immune control in beta cell replacement?
To apply for Microgels for localized immune control in beta cell replacement, confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases.